Raise History
Our science has attracted over $30 million from investors, public funds, grants, and incubator investments so far.
Scimar’s operations are supported by our investors. Since launching our seed round in 2018, we’ve attracted over $17.5 million in private investments from more than 93 investors.
In early 2022, we launched our Series A round to build infrastructure, accelerate our research and clinical trials, and support our subsequent market launches of SciMar NuPa Daily: a nutraceutical designed to protect hepatalin production.
- It’s personal. They know somebody impacted by diabetes and want to be a part of the solution.
- It’s the science. The data are clear: hepatalin is the missing link.
- It’s the company. Scimar has a proven track record of success.
- It’s the approach. We create solutions combining medical and lifestyle interventions.
- It’s the reasoning. We care about solving the problem, not just selling products.
- It’s the potential. Our product suite is designed to disrupt a trillion-dollar market.
| Public funds, grants, and incubator investments (attracted by Dr. Lautt while working as an academic): | $17.3 million |
| Seed round, 2018: | $9.5 million |
| Bridge round, 2021: | $4.5 million in preferred convertible shares |
| Series A round, 2022: | $3.7 million |
*All funds expressed in Canadian dollars